There is a strong opportunity in the heart failure (HF) space for new agents that could reduce HF-associated hospitalisations ...

A meta-analysis has demonstrated consistent efficacy in heart failure outcomes with SGLT2 inhibitors regardless of disease ...

Experts discuss the relationship between obesity and heart failure while referencing new clinical trial results.

The European Commission (EC) has authorised GSK’s Arexvy for active immunisation against LRTD caused by RSV in adults aged 50 ...

If approved, Novo Nordisk's Ozempic will become the first GLP-1 therapy option for patients with type 2 diabetes and chronic ...

Subsequently, AI has become an important tool to overcome challenges and support the development of personalised care. One ...

The FDA has granted ODD status to Nuvectis Pharma’s NXP800 for ARID1a-deficient ovarian, fallopian tube and primary ...

The FDA cited concerns with the API manufacturing plant including falsifying production records and failing to follow proper ...

The French government funds will support clinical development for T cell-activating monoclonal antibody and another project.

GlobalData tracks 14 drugs in development for Cystitis by 14 companies/universities/institutes. The top development phase for Cystitis is preclinical, with six drugs in that stage.

GlobalData tracks 15 drugs in development for Leiomyoma by 16 companies/universities/institutes. The top development phase for Leiomyoma is preclinical, with six drugs in that stage.

GlobalData tracks 7 drugs in development for Corneal Ulcers by seven companies/universities/institutes. The top development phase for Corneal Ulcers is preclinical, with three drugs in that stage.